← Back to Clinical Trials
Recruiting NCT05654012

NCT05654012 Migraine in Adolescents

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05654012
Status Recruiting
Phase
Sponsor Washington University School of Medicine
Condition Migraine
Study Type INTERVENTIONAL
Enrollment 250 participants
Start Date 2023-06-01
Primary Completion 2028-03-15

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 13 Years
Study Type INTERVENTIONAL
Interventions
MRIThermal StimuliPressure stimuli

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 250 participants in total. It began in 2023-06-01 with a primary completion date of 2028-03-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents Aim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset. Aim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes preceding vs. following migraine onset. Aim 3. To identify psychophysical and neural factors predicting migraine prognosis in adolescents with migraine.

Eligibility Criteria

Inclusion criteria for healthy participants: 1. Age 10-13 2. Males or females (biological sex) 3. Not diagnosed with migraine or having migraine symptoms 4. With a first degree relative diagnosed with migraine (for the Fam-His group) or without a first or a second degree relative diagnosed with migraine (for the No-Fam-His group) Inclusion criteria for participants with migraine: 1. Age 10-13 2. Males or females (biological sex) 3. Diagnosed with migraine or having migraine symptoms 4. Migraine duration \> 6 months 5. Without preventative treatment or with stable preventative treatment for migraine (no change in intervention in the last 6 months) Exclusion Criteria for the healthy group: * Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion: 1. Diagnosis of any chronic pain syndrome 2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder 3. Taking pain or psychiatric medications regularly 4. Having an MRI contraindication such as metal in the body or claustrophobia 5. Not able to understand and communicate in English Exclusion Criteria for the migraine group * Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion: 1. Diagnosis of any chronic pain syndrome other than migraine 2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder 3. Having an MRI contraindication such as metal in the body or claustrophobia 4. Not able to understand and communicate in English

Contact & Investigator

Central Contact

Alana McMichael, MA

✉ painlab@wustl.edu

📞 314-273-6194

Principal Investigator

Hadas Nahman-Averbuch, PhD

PRINCIPAL INVESTIGATOR

Washington University School of Medicine

Frequently Asked Questions

Who can join the NCT05654012 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 13 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05654012 currently recruiting?

Yes, NCT05654012 is actively recruiting participants. Contact the research team at painlab@wustl.edu for enrollment information.

Where is the NCT05654012 trial being conducted?

This trial is being conducted at St Louis, United States.

Who is sponsoring the NCT05654012 clinical trial?

NCT05654012 is sponsored by Washington University School of Medicine. The principal investigator is Hadas Nahman-Averbuch, PhD at Washington University School of Medicine. The trial plans to enroll 250 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology